Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice.

ERJ Open Res · 2018 · PMC6194204 · PMID 30364342

Europe PMC DOI

hedged sentence

0.1120

closest p · 2.2× alpha

0.1120

boldest claim

The sentences

a nonsignificant trendp=0.112not close (p > 0.1)

There was a nonsignificant trend toward discontinuation of nintedanib in those previously intolerant of pirfenidone (p=0.112).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.